Long-term albumin infusion in decompensated cirrhosis:A review of current literature  

作　　者：Yu Jun Wong Rahul Kumar Yu Jing Jonathan Chua Tiing Leong Ang 

机构地区：[1]Department ofGastroenterology and Hepatology,Changi General Hospital,Singapore 529889,Singapore [2]Department of Internal Medicine,Yong Loo Lin School of Medicine,Singapore 117597,Singapore

出　　处：《World Journal of Hepatology》2021年第4期421-432,共12页世界肝病学杂志（英文版）（电子版）

基　　金：Supported by Nurturing Clinician Scientist Scheme Award by SingHealth Duke-NUS Medicine Academic Medicine Programme(Medicine ACP),Changi General Hospital Research Grant.

摘　　要：Decompensated cirrhosis is characterized by chronic inflammation and severe portal hypertension leading to systemic circulatory dysfunction.Albumin infusion has been widely used in decompensated cirrhosis in patients with spontaneous bacterial peritonitis,large-volume paracentesis and hepatorenal syndrome.Emerging data suggest long-term albumin infusion has both oncotic and non-oncotic properties which may improve the clinical outcomes in decompensated cirrhosis patients.We review the current literature on both the established and potential role of albumin,and specifically address the controversies of long-term albumin infusion in decompensated cirrhosis patients.

关 键 词：ALBUMIN CIRRHOSIS Hepatic encephalopathy Hepatorenal syndrome Acuteon-chronic liver failure Spontaneous bacterial peritonitis Large-volume paracentesis 

分 类 号：R575.2[医药卫生—消化系统]